Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Third Quarter 2024 Results • Third Quarter 2024 Financial Results ◦ Revenue of $1,030 million, organic constant currency growth of 1% ◦ Reported Net Income of $364 million, Adjusted Net Income of $66 million ◦ Adjusted EBITD ...

Third Quarter 2024 Financial Results Revenue of $1,030 million, organic constant currency growth of 1% Reported Net Income of $364 million, Adjusted Net Income of $66 million Adjusted EBITDA of $163 million, or 15.8% of Revenue Reported EPS of $0.73, Adjusted EPS of $0.13 Net leverage ratio of 4.3x Adjusted EBITDA Pre-tax gain of $640 million from July 2024 divestiture of the aqua business Tightening full year 2024 financial guidance to reflect current assumptions: Revenue of $4,420 to $4,450 million, ...

NEW YORK, Nov. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=110874&from=4CL ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Invest ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=110729& ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-h ...

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health on behalf of investors who purchased its securities between November 7, 2023, and June 26, 2024, due to significant stock price decline following FDA approval updates [1][5]. Company Overview - Elanco Animal Health develops products for pets and farm animals, including Zenrelia, an oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a parasiticide for dogs [2]. FDA Approval Timeline - In November 2023, Elanco set a timeline for U.S. FDA approval of Zenrelia and Credelio Quattro in the first half of 2024 [3]. - By May 2024, Elanco updated its timeline, expecting Zenrelia's approval and commercial launch in Q3 2024, and Credelio Quattro's approval in Q3 2024 with a launch in Q4 2024 [3]. - On June 27, 2024, Elanco indicated that Zenrelia would include a boxed safety warning, potentially slowing product adoption by approximately 25%, with expected FDA approval in Q3 2024 and a commercial launch in Q4 2024 for both products [4]. Stock Price Impact - Following the announcement regarding the FDA approval timelines and safety warnings, Elanco's stock price fell by $3.69 per share, or 20%, closing at $14.28 per share on June 27, 2024 [5].

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Elanco Animal Health Incorporated regarding a class action lawsuit due to alleged misleading statements and omissions related to product safety and approval timelines [1][2]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 7, 2023, to June 26, 2024 [2]. - Allegations include that Elanco misrepresented the safety of Zenrelia, a canine dermatology product, and was unlikely to meet its own timeline for U.S. approval and launch of Zenrelia and Credelio Quattro [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by December 6, 2024, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].